Followers | 37 |
Posts | 4190 |
Boards Moderated | 0 |
Alias Born | 10/18/2016 |
Monday, November 20, 2017 10:16:38 AM
India Globalization Capital (NYSE American: IGC) today reported financial results for the second quarter ended September 30, 2017, as well as an overview of recent operational highlights. The company’s legacy division which consists of rental of heavy equipment, commodities trading, and real estate management delivered revenue of $235,648 for the three months ended September 30, 2017, a sharp increase compared to $162,163 for the three months ended September 30, 2016. The increase was primarily driven by increased volume of business. At the end of the second quarter, the company’s cash and cash equivalents along with restricted cash was $597,026 and working capital of $803,769. IGC expects to raise money for the canna-pharmaceutical business, specifically to immediately begin marketing IGC-AD1. Additionally, IGC reported its progress made on its six provisional patent filings in the phytocannabinoid-based combination therapy space for the indications of pain, medical refractory epilepsy, and cachexia. “Independent of our longer-term FDA clinical trial process, our near-term goal is to commercialize our liquid formulation for Alzheimer’s as a Complimentary and Alternative Medicine (CAM) sold through licensed medical cannabis dispensaries in the U.S., and internationally in Canada and Germany,” IGC CEO Ram Mukunda stated in the news release.
To view the full press release, visit http://nnw.fm/0lSPi
About IGC
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information, please visit www.IGCinc.us.
Recent IGC News
- IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment • Business Wire • 09/18/2024 12:00:00 PM
- IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease • Business Wire • 09/04/2024 12:00:00 PM
- IGC Announces Results of its 2024 Annual Stockholders Meeting • Business Wire • 08/26/2024 11:00:00 PM
- IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease • Business Wire • 08/22/2024 01:00:00 PM
- IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist • Business Wire • 08/20/2024 12:00:00 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/14/2024 08:23:18 PM
- IGC Pharma Reports First Quarter Fiscal 2025 Results • Business Wire • 08/09/2024 01:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 08:03:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 06:38:52 PM
- IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target • Business Wire • 07/18/2024 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 07/09/2024 06:17:37 PM
- Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile • Business Wire • 07/09/2024 01:10:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 07/08/2024 08:07:05 PM
- IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease • Business Wire • 06/25/2024 01:00:00 PM
- IGC Reports Financial Results for Fiscal Year Ended March 31, 2024 • Business Wire • 06/24/2024 11:30:00 PM
- IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets • Business Wire • 06/18/2024 01:00:00 PM
- IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol • Business Wire • 06/10/2024 01:00:00 PM
- IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1 • Business Wire • 05/28/2024 01:00:00 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 05/22/2024 01:20:27 AM
- IGC Pharma to Attend BIO International Convention 2024 • Business Wire • 05/21/2024 06:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2024 01:54:41 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2024 01:53:35 AM
- IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two • Business Wire • 04/16/2024 11:00:00 AM
- IGC Pharma Adds Advisor in Artificial Intelligence • Business Wire • 04/09/2024 01:00:00 PM
- IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock • Business Wire • 03/26/2024 07:00:00 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM